FIG. 1.

Selected redox chemotherapeutics in clinical development for oncological indications. The therapeutic performance of redox chemotherapeutics in advanced phases of clinical testing suggests that they represent novel pharmacological agents that target cancer depicted here as an invasive tumor in the process of metastatic cell dissemination (center insert). Selected investigational redox chemotherapeutics are depicted (clockwise from upper right): the orally active prooxidants elesclomol and artemisinin, the infusional redox drug ascorbate, the infusional SOD mimetic mangafodipir, the infusional redox cycler motexafin gadolinium, the orally active SOD1 inhibitor ATN-224, the infusional thioredoxin inhibitor PX-12, and the infusional arsenical darinaparsin. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com/ars).